The obesity epidemic impacts heavily on cardiovascular health, in part owing to changes in cardiac metabolism. AMP-activated protein kinase (AMPK) is a key regulator of energy homeostasis in the heart and is regulated by -adrenoceptors ( -ARs) in normal conditions. In obesity, chronic sympathetic overactivation leads to impaired cardiac -AR responsiveness, although it is unclear whether AMPK signalling, downstream of -ARs, contributes to this dysfunction. Therefore, we aimed to determine whether reduced AMPK signalling is responsible for the reduced -AR responsiveness in obesity. In isolated hearts of lean and obese Zucker rats, we tested -AR responsiveness to the 1 -AR agonist isoprenaline (ISO, 1 × 10 −10 to 5 × 10 −8 M) in the absence and presence of the AMPK inhibitor, compound C (CC, 10 M). The 1 -AR expression and AMPK phosphorylation were assessed by Western blot. -Adrenergic responsiveness was reduced in the hearts of obese rats (logEC 50 of ISO-developed pressure dose-response curves: lean −8.53 ± 0.13 × 10 x M versus obese −8.35 ± 0.10 × 10 x M ; P < 0.05 lean versus obese, n = 6 per group). This difference was not apparent after AMPK inhibition (logEC 50 of ISO-developed pressure curves: lean CC −8.19 ± 0.12 × 10 x M versus obese CC 8.17 ± 0.13 × 10 x M, P < 0.05, n = 6 per group). 1 -Adrenergic receptor expression and AMPK phosphorylation were reduced in hearts of obese rats (AMPK at Thr 172 : lean 1.73 ± 0.17 a.u. versus lean CC 0.81 ± 0.13 a.u., and obese 1.18 ± 0.09 a.u. versus obese CC 0.81 ± 0.16 a.u., P < 0.05, n = 6 per group). Thus, a direct functional link between -adrenergic responsiveness and AMPK signalling in the heart exists, and AMPK might be an important target to restore the reduced cardiac -adrenergic responsiveness in obesity.
INTRODUCTION
AMP-activated protein kinase (AMPK) is a key sensor and regulator of energy homeostasis in the heart (Hardie, Hawley, & Scott, 2006) .
In general, activation of AMPK, by an increase in the AMP:ATP ratio owing to an increase in energy demand or cellular stress, triggers corrective changes in energy status. AMPK promotes energyproducing processes and reduces energy-consuming processes and is a crucial kinase for protection against the ischaemic stress response (Lamberts et al., 2009; Young, 2008 The rapid expansion of the obesity and type 2 diabetes coepidemics impacts heavily on cardiovascular health. These conditions featuring long-term changes in cardiac metabolism are characterized by changes in the autonomic control of cardiovascular function (Lambert, Straznicky, Lambert, Dixon, & Schlaich, 2010) . Higher levels of muscle (Agapitov, Correia, Sinkey, & Haynes, 2008; Huggett et al., 2003) and cardiac (Thaung, Baldi et al., 2015) sympathetic nerve activity indicate a systemic sympathetic overdrive, but importantly, increased sympathetic input directly to the heart. Consequently, several studies have demonstrated decreased -adrenoceptor ( -AR) Experimental Physiology. 2018;103:1067-1075.
wileyonlinelibrary.com/journal/eph
New Findings
• What is the central question of the study?
Is the reduced signalling of AMP-activated protein kinase (AMPK), a key regulator of energy homeostasis in the heart, responsible for the reduced -adrenergic responsiveness of the heart in obesity?
• What is the main finding and its importance?
Inhibition of AMPK in isolated hearts prevented the reduced cardiac -adrenergic responsiveness of obese rats, which was accompanied by reduced phosphorylation of AMPK, a proxy of AMPK activity. This suggests a direct functional link between -adrenergic responsiveness and AMPK signalling in the heart, and it suggests that AMPK might be an important target to restore the -adrenergic responsiveness in the heart in obesity.
expression in, and reduced -AR responsiveness of, the heart in obesity (Bass & Ritter, 1985; Bunag, Tomita, & Krizsan, 1990; Chatelain et al., 1981; Jiang et al., 2015; Sherwood, Hill, Blumenthal, Johnson, & Hinderliter, 2017; Strassheim, Houslay, & Milligan, 1992) , with similar reports in diabetes (Cook, Bussey, Mellor, Cragg, & Lamberts, 2017; Dincer et al., 2001; Dincer, Onay, Ari, Ozcelikay, & Altan, 1998; Lamberts et al., 2014; Thaung, Baldi et al., 2015) .
Although weight loss and exercise remain the most important therapies against obesity and its related cardiovascular complications, the lack of compliance to lifestyle changes and variable cardiovascular responses to weight loss often necessitate drug therapy (Carnagarin et al., 2017) . The use of -AR blockers, the most obvious approach to target the autonomically induced -AR dysregulation in the heart, is however, commonly advised against in obese individuals owing to their unfavourable metabolic effects (Gress, Nieto, Shahar, Wofford, & Brancati, 2000; Sharma, Pischon, Hardt, Kunz, & Luft, 2001) . Therefore, it is of clinical importance to understand the underlying mechanisms of dysfunctional cardiac -AR regulation in the metabolic syndrome, so that new potential therapeutic targets can be identified.
Interestingly, -AR regulation in the healthy heart is linked to AMPK activity, with stimulation of -ARs increasing AMPK activity Li et al., 2010; Perez-Schindler, Philp, Baar, & Hernandez-Cascales, 2011) . Although reduced AMPK activation has been proposed to be one of the main factors responsible for disturbed metabolic regulation in obesity (Watt et al., 2006) , it is unknown whether reduced AMPK signalling, downstream of -ARs, is responsible for the reduced -AR responsiveness in obesity. Hence, we aimed to assess the involvement of AMPK in the dysfunctional -AR responsiveness of the heart in obesity. To this end, in isolated hearts of lean and obese Zucker rats, a reliable model of metabolic syndrome (Jiang et al., 2015; Kanasaki & Koya, 2011) , we measured -AR responsiveness in the absence and presence of the AMPK inhibitor compound C (CC), alongside determination of 1 -AR and AMPK expression levels.
METHODS

Ethical approval
The Animal Ethics Committee of the University of Otago, New
Zealand approved this study (ET19-11), and all the experiments were conducted according to the guidelines of the New Zealand Animal Welfare Act (1999). The investigators understand the ethical principles under which Experimental Physiology operates, and our work complies with the animal ethics checklist of the journal.
Animals
Experiments were conducted on 16-week-old male obese (fa/fa)
Zucker rats (n = 12) and their lean (+/+ or +/fa) littermates (n = 12).
Animals were obtained from an in-house colony, with the original breeding pairs obtained from Charles River Laboratories (Wilmington, MA, USA). Animals had ad libitum access to food and water.
Cardiac function and -AR responsiveness
Intrinsic cardiac function and responsiveness to -AR stimulation were determined using Langendorff-perfused isolated hearts, as previously described (Lamberts et al., 2009; Thaung, Baldi et al., 2015) . In brief, animals were deeply anaesthetized with pentobarbital (60 mg kg −1 ) (Provit, Mississauga, Ontario, Canada), and when the pedal withdrawal reflex was absent the heart was excised. The isolated heart was mounted on a Langendorff apparatus, and the aorta was perfused retrogradely with Krebs-Henseleit buffer (KHB) at 37 • C at a constant pressure of 80 mmHg. CaCl 2 , 25.0 NaHCO 3 and 11.0 glucose, and it was continuously equilibrated with 95% O 2 and 5% CO 2 (pH 7.4). A custom-made balloon-tipped catheter connected to a hydrostatic pressure transducer was inserted into the left ventricle to measure isovolumetric left ventricular (LV) pressure. The LV balloon was inflated to determine the volume at which maximal isovolumetric LV pressure was developed (LV V max ), and the balloon volume was adjusted to 95% of the V max for the entire experiment. Two stimulating electrodes, one at the apex and the other on the right atrium, were used for pacing of the heart at 5 Hz (300 beats min −1 ), mimicking in vivo heart rate (Bussey, de Leeuw, & Lamberts, 2014) . The isovolumetric LV developed pressure (LVP dev ), LV diastolic pressure (LVP dia ), maximal rate of pressure development (+dP/dt max ), maximal rate of relaxation (−dP/dt max ) and time constant of relaxation ( ) were calculated from the LV pressure trace.
Both obese and lean rats were divided into two groups: TimeControl and Treatment. After stabilization for 10 min, the hearts from all four groups were exposed to incremental doses of isoprenaline (ISO, 1 -agonist; from 1 × 10 −10 to 5 × 10 −8 M, 5 min per dose) to assess responsiveness to -AR stimulation, followed by ISO washout. (Schouten, Allaart, & Westerhof, 1992; Thaung, Yao et al., 2015) . At the end of the experiment, the isolated hearts of both groups were frozen in the presence or absence of CC.
Protein analysis
The protein expression levels of AMPK, phosphorylated AMPK at Thr 172 (pAMPK; Bouwman et al., 2010; Lamberts et al., 2009 ) and 1 -AR (Thaung, Baldi et al., 2015; Thaung, Yao et al., 2015) were determined as described previously. Briefly, protein lysates from LV tissue were separated on 12% SDS-polyacrylamide gels and transferred onto polyvinylidene fluoride membranes, which were subsequently probed with specific polyclonal antibodies against AMPK, pAMPK (both rabbit, 1:1000 dilution; Cell Signaling Technology, Danvers, MA, USA) or 1 -AR (rabbit, 1:500 dilution in 2% BSA; Novus Biologicals, Littleton, CO, USA), and voltage-dependent anion channel (VDAC; porcine, 1:10,000 dilution in 2% milk; Abcam, Cambridge, UK). Proteins were visualized using an enhanced chemiluminescence detection system (Supersignal Westpico; Thermo Fisher, Scoresby, Victoria, Australia). The AMPK and 1 -AR protein expressions were normalized to VDAC to correct for protein loading, whereas pAMPK expression was normalized to AMPK expression.
Data analysis
Individual differences occurred in baseline values between hearts; therefore, in order to determine the -adrenergic responsiveness accurately, the absolute ISO dose-response curves of each parameter (LVP dev , +dP/dt max and −dP/dt max ) were normalized to their own baseline and to the value at maximal -AR stimulation. These normalized isoprenaline dose-response curves were fitted with symmetrical sigmoidal relationships using non-linear regression techniques available in Graphpad Prism version 7. The resulting lines of best fit are described as follows:
where y min and y max are the minimal and maximal values of the unconstrained fitted curves. The EC 50 is the value of x yielding the half-maximal value of y, and n H specifies the Hill slope at logEC 50 . The accuracy of fit is indicated as the square of the correlation coefficient,
Differences between groups in animal characteristics, basal heart function data, and logEC 50 were determined using Student's unpaired t test, whereas differences in -AR responsiveness, functional capacity and protein analysis were tested via a two-way ANOVA, followed by Sidak's multiple comparisons analysis, both using Graphpad Prism version 7 (GraphPad Software, La Jolla, CA, USA). A value of P < 0.05 was considered statistically significant. Results are presented as means ± SD.
RESULTS
Animal characteristics
The obese (fa/fa) Zucker rats exhibited increased body weight, increased heart weight, without a change in LV volume, and unchanged non-fasted plasma glucose concentrations (Table 1) ; all indicative of metabolic syndrome with concentric hypertrophic remodelling, as observed previously (Bussey et al., 2014; Jiang et al., 2015) .
Basal heart function in obesity
In basal conditions after 10 min of stabilization, the contraction and relaxation parameters (LVP dia , LVP dev and ) were not different between the hearts from the lean and obese animals, whereas +dP/dt max and −dP/dt max were both faster in the lean group, although this difference was lost after normalization to LVP dev (Table 2 ).
Reduced cardiac -adrenergic responsiveness in obesity
-Adrenergic receptor stimulation increased contractility and accelerated relaxation, as indicated by increased values for LVP dev , +dP/dt max and −dP/dt max with incrementing concentrations of the -AR agonist, ISO (Figure 1a-c) . However, the absolute ISO doseresponse curves were not different between hearts from lean and obese animals. After normalization to baseline and to the LVP dev at maximal -AR stimulation, the ISO dose-response curves for all three parameters were significantly shifted rightwards in the obese group (Figure 1d-f ). This was confirmed by significant differences 
TA B L E 1 Animal characteristics
AMPK inhibition blunts reduced -adrenergic responsiveness in obesity
After washout of the ISO from the first dose-response curve, addition of CC (10 M) reduced LVP dev (lean, from 65 ± 6 to 59 ± 7 mmHg versus obese, from 71 ± 8 to 65 ± 9 mmHg), +dP/dt max (lean, from Although absolute -AR agonist-response relationships were not different between hearts from lean and obese animals (ISO effect, no obese effect or interaction), normalization showed a significant overall rightward shift of the dose-response curves in the obese group for LVP dev (d), +dP/dt max (e) and −dP/dt max (f) (ISO effect, obese effect and interaction), indicating reduced -adrenergic responsiveness in obesity. Two-way ANOVA followed by Sidak's multiple comparisons analysis, n = 6 per group, * P < 0.05 versus baseline, # P < 0.05 versus lean; data are presented as means ± SD -Adrenergic responsiveness in lean and obese hearts after AMPK inhibition. (a-f) Incrementing concentrations of the -AR agonist isoprenaline (ISO) increased left ventricular developed pressure (LVP dev ; a,d), maximal rate of pressure development (+dP/dt max ; b,e) and maximal rate of left ventricular relaxation (−dP/dt max ; c,f) in isolated Langendorff-perfused hearts of lean and obese Zucker rats in the presence of 10 M AMPK inhibitor compound C (CC). The ISO dose-response curves were shifted markedly to the right in the presence of CC for all parameters in the hearts from both lean and obese animals. After AMPK inhibition, the ISO dose-response curves were not different between hearts from lean and obese animals (ISO effect, no obese effect or interaction). Two-way ANOVA followed by Sidak's multiple comparisons analysis, n = 6 per group, * P < 0.05 versus baseline; data are presented as means ± SD and −dP/dt max , lean CC −8.14 ± 0.10 × 10 x M versus obese CC −8.12 ± 0.15 × 10 x M; all P > 0.05 lean CC versus obese CC; Student's unpaired t test, n = 6 per group). Interestingly, the normalized ISO dose-response curves were shifted markedly to the right in the presence of CC for all three parameters in hearts from both lean and 
Preserved contractile, but reduced -adrenergic, capacity in obese rats
The reduced -adrenergic responsiveness of the obese heart could be the result of an overall reduced contractile capacity; therefore, a postextrasystolic rest potentiation protocol was performed. No differences were apparent in maximal LV pressure (P max ) in the isolated hearts of lean or obese rats, either without or with AMPK inhibition (Figure 3a) .
The highest developed LV pressure induced by the -AR agonist ISO (P Iso ; at 5 × 10 −8 M) was reduced in isolated hearts of obese compared with lean rats (Figure 3b ). AMPK inhibition significantly lowered the P Iso in the heart of the lean animals, but not in the obese group, thereby abolishing the difference in P Iso between the two groups.
Consequently, the cumulative changes in LVP dev (baseline, P Iso and P max ) confirmed that although the -adrenergic capacity was reduced in hearts from obese rats, the total contractile reserve remained constant (Figure 3c ).
AMPK inhibition lowers phosphorylated AMPK expression
At the end of the experiment, the isolated hearts were frozen in the presence or absence of CC, and protein analysis was performed. The expression level of AMPK was determined (Figure 4a,b) , alongside the extent of its phosphorylation at Thr 172 , as a proxy of its activity (Figure 4c,d Obese F I G U R E 3 Contractile and -adrenergic capacity after AMPK inhibition in isolated hearts of lean and obese Zucker rats. (a) No differences in postextrasystolic rest potentiation-induced maximal developed left ventricular pressures (P max ) in isolated hearts of lean and obese rats, either with or without 10 M AMPK-inhibitor compound C (CC; no CC effect, obese effect or interaction). (b) The highest developed left ventricular pressure (LVP dev ) induced by the -AR agonist isoprenaline (P Iso ; 5 × 10 −8 M) was lower in isolated hearts from obese rats (no obese effect, CC effect and an interaction). (c) Consequently, the cumulative changes in LVP dev (baseline, P Iso and P max ) showed that the -adrenergic capacity of the obese hearts was reduced, although the total contractile reserve remained. Two-way ANOVA followed by Sidak's multiple comparisons analysis, n = 6 per group, * P < 0.05 versus P Iso ; # P < 0.05 versus lean; data are presented as means ± SD, except panel (c), which shows only mean values (Thr 172 ) , normalized to total AMPK, was reduced in hearts from obese Zucker rats compared with lean rats, whereas addition of CC reduced pAMPK levels in both groups (CC effect, obese effect and interaction). (e,f) 1 -Adrenoceptor protein expression, normalized to VDAC expression, was 36% lower in the left ventricle from obese rats compared with lean rats (obese effect, no CC effect or interaction). Two-way ANOVA followed by Sidak's multiple comparisons analysis, n = 6 per group, * P < 0.05 versus control; # P < 0.05 versus lean, arbitrary units (a.u.); data are presented as means ± SD present. However, the presence of 10 M CC reduced the level of pAMPK at Thr 172 in the hearts of both lean and obese rats, confirming the efficacy of the AMPK inhibition by CC. Moreover, in the absence of the AMPK inhibitor the obese hearts had reduced levels of pAMPK (P < 0.05).
The 1 -AR protein expression was 36% lower in the LV from obese rats compared with hearts from lean rats, a difference that was not affected by AMPK inhibition with CC (Figure 4e,f) .
DISCUSSION
In the present study, we found a reduced -adrenergic responsiveness in the hearts of obese rats. This difference in -adrenergic responsiveness disappeared after AMPK inhibition and was associated with reduced 1 -AR expression and AMPK phosphorylation. This shows a direct functional link between -adrenergic responsiveness and AMPK in the heart and suggests that AMPK might be an important alternative downstream target to restore the reduced cardiac -adrenergic responsiveness in obesity.
Obese Zucker rats have a homozygous missense mutation in the leptin receptor gene (fa/fa), leading to impaired satiety signalling and hyperphagia. The Zucker strain is a well-accepted model of obesity (Chua et al., 1996; Kanasaki & Koya, 2011; Phillips et al., 1996) , and the obese rats were compared with their own lean littermates as in-strain controls. Our obese (fa/fa) Zucker rats showed structural and metabolic changes indicative of the metabolic syndrome with concentric hypertrophic remodelling, without any noticeable differences in baseline cardiac contraction or relaxation, as shown previously (Bussey et al., 2014; Jiang et al., 2015) . In addition, in the present study we showed that the maximal capacity of the heart of the obese Zucker rat is not different from its lean littermate, indicating that at this stage the contractile reserve of the obese heart remains.
Our observation of reduced -adrenergic responsiveness in hearts of obese rats confirms previous findings, not only in isolated rat and rabbit hearts (Carroll et al., 1997; Carroll, Kyser, & Martin, 2002; Jiang et al., 2015; Lima-Leopoldo et al., 2011) , but also using cardiac membranes (Bass & Ritter, 1985; Chatelain et al., 1981; Strassheim et al., 1992) , and more importantly, in vivo assessment in conscious conditions (Bunag et al., 1990; Bussey et al., 2014) . In some studies, it was not possible to associate the reduced -adrenergic responsiveness of the obese heart with a downregulation of the -ARs (Carroll et al., 2002; Ernsberger, Koletsky, Baskin, & Foley, 1994; Ferron et al., 2015; Hohl et al., 1993; Minhas et al., 2005; Vileigas et al., 2016) , potentially owing to differences in obese animal models and technical approaches.
However, in several other studies, using obese Zucker rats, downregulation of -ARs was observed (Chatelain et al., 1981; Jiang et al., 2015; Strassheim et al., 1992) , as found in our study. Given that we recently showed in Zucker diabetic fatty rats that only the 1 -AR subtype was directly responsible for the contractile responses (Cook et al., 2017) , we only confirmed the reduced expression of the 1 -AR subtype. This, however, does not exclude the possibility that other -AR subtypes could be affected during obesity (Chatelain et al., 1981; Jiang et al., 2015; Strassheim et al., 1992) or play an important supportive role in the pathophysiology of obesity and diabetes (Cook et al., 2017; Li et al., 2010; Perez-Schindler et al., 2011) . More importantly,
given that from a clinical viewpoint targeting -ARs with -blockers is commonly advised against in obese individuals owing to their unfavourable metabolic effects (Gress et al., 2000; Sharma et al., 2001) and given that -AR downregulation is most probably not the sole mechanism underlying the reduced -adrenergic responsiveness of the heart in obesity (Ferron et al., 2015; Vileigas et al., 2016) , alternative mechanisms should be explored.
AMPK is a key sensor and regulator of energy homeostasis in the heart (Hardie et al., 2006) and has been proposed to be one of the main factors responsible for the disturbed metabolic regulation in obesity (Watt et al., 2006) . In general, it is thought that AMPK stimulates energy-producing processes, especially fatty acid metabolism, and inhibits energy-consuming processes. We found in the hearts of our obese Zucker rats that AMPK protein expression was not affected;
however, phosphorylation at Thr127, an indication of AMPK activity, was reduced. This is in agreement with studies in hearts of obese ob/ob mice (Wang & Unger, 2005) , and the crossover model of obese
Dahl salt-sensitive/Zucker rats (Matsuura et al., 2015) , and suggests a disturbed cardiac energy homeostasis. Moreover, others did find a reduced AMPK protein expression in diet-induced obese mice (Ko et al., 2009) or rats (Lindholm et al., 2013) , although in obese Ossabaw swine no changes in protein expression or phosphorylation of AMPK were observed (Moberly et al., 2013) .
In our study, AMPK inhibition lowered overall cardiac function and slowed relaxation in the hearts of both lean and obese animals, which can be expected if energy-producing processes are inhibited and energy-consuming processes stimulated. In addition, others have shown that adrenergic stimulation increases the phosphorylation of AMPK, through either 1 -ARs or 1 -ARs (Xu et al., 2007) , in healthy hearts.
During sympathetic activation, when there is increased metabolic demand, it is expected that AMPK will be activated and thereby safeguard energy homeostasis. Maximal -AR stimulation with dobutamine has been observed to elicit lower cardiac pAMPK levels in diabetic db/db mice (Daniels et al., 2010) , whereas ISO instigated cardiomyocyte apoptosis and heart failure via AMPK (Zhuo et al., 2013) , and the non-specific AMPK stimulator, metformin, protected the myocardium against ISO-induced injury (Cai et al., 2014) . However, none of these studies determined a direct functional link between AMPK and -adrenergic responsiveness. Our study shows, for the first time, that inhibition of AMPK reduced the cardiac -adrenergic responsiveness in lean and obese rats and abolished the difference in the -adrenergic response between the two groups.
This shows that AMPK signalling is crucial for the positive inotropic -adrenergic response, suggesting a direct functional link between AMPK and -adrenergic responsiveness in the heart. Moreover, as this link is significantly disturbed in obesity, it also implies that the reduced cardiac -adrenergic contractile responsiveness in obesity is attributable, at least in part, to lower activation of AMPK.
Our study used isolated hearts; therefore, care should be taken to translate our findings to the in vivo setting. Nonetheless, the -AR responsiveness of the heart per se is best assessed in the absence of confounding haemodynamic and humoral effects of the systemic circulation and of neuronal input. Moreover, it has been demonstrated that in addition to the defined role of AMPK as a metabolic energy gauge in the heart, AMPK can also directly phosphorylate the Ser 150 site of cardiac troponin I and thereby increase myofilament calcium sensitivity (Nixon et al., 2012) ; therefore, non-metabolic effects of AMPK on -AR responsiveness in obesity cannot be excluded.
Tentatively, AMPK has been proposed to phosphorylate adrenergic receptors, and consequently, regulate their function, which could be considered as a negative feedback regulation to protect the heart (Lefkowitz & Caron, 1986 ).
In summary, we found reduced -adrenergic responsiveness in the hearts of obese Zucker rats. This difference disappeared after AMPK inhibition and was associated with reduced 1 -AR expression and AMPK phosphorylation. This shows a direct functional relationship between AMPK and -adrenergic responsiveness in the heart, a crucial link that is impaired during obesity. Clinically, these observations are important because they indicate that the impaired adrenergic responsiveness of the heart in obesity does not necessarily have to be targeted solely by the use of unfavourable -blockers, but that alternative signalling molecules, such as AMPK, might be more favourable to target the cardiac metabolic derangements.
